Navigation Links
NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets

In this analysis, time to reach therapeutic drug concentration levels of 20 ng/ml was measured for healthy volunteers in the NVD003 study. This analysis yielded the following results:

-- 79% of subjects using the 10 mg zolpidem oral spray reached therapeutic levels at 15 minutes post-dosing while only 26% of subjects using 10 mg tablets reached therapeutic levels at that time point. The difference between these two rates is statistically significant (p less than 0.0001).

-- 65% of subjects using the 5 mg zolpidem oral spray reached therapeutic levels at 15 minutes post-dosing while only 19% of subjects in the tablet group reached therapeutic levels by 15 minutes. This result is statistically significant (p less than 0.0003) in favor of the oral spray group.

-- A cross analysis between 5 mg oral spray and 10 mg Ambien(R) tablets showed that subjects using 5 mg oral spray reached therapeutic levels significantly faster at 15 minutes post-dosing than those using 10 mg tablets. These results are statistically significant (p less than 0.0002).

Overall analysis of the number of subjects reaching therapeutic levels by 15 minutes post-dosing suggests the potential of faster induction of sleep at lower drug doses may be achieved by using oral sprays.

Additional PD Assessment: Change in DSST to Measure Sedation

Patients in both zolpidem oral spray studies performed the digital symbol substitution test (DSST). According to Dr. Tom Roth, Director of Sleep Medicine at Henry Ford Hospital in Detroit, "DSST measurements are a scientifically, well accepted surrogate for sedation and a significant reduction in DSST score may indicate earlier onset of therapeutic action for these drugs."

NovaDel's findings from its pharmacodynamic study using DSST yielded the following results for healthy volunteers in the NVD003 study:

-- Subjects using the 10 mg oral spray showed a nearly fourfold greater reduction of DSST score at 13 minutes
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Pranoprofen Market, ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation ... an inflammatory drug, pranoprofen was later developed into ... the trade name of pranopulin for the treatment ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2
... Sally Jobe is among the first diagnostic imaging networks in the ... of cancer. Screening Breast Ultrasound (SBU) is a highly effective technology developed ... factors. , , , ... ultrasound is part of our ongoing mission to provide comprehensive breast care ...
... MENLO PARK, Calif. , July 6 Crux Biomedical®Inc. ... its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate ... (VCF). The Crux VCF is a retrievable, implantable filter which ... potentially fatal pulmonary embolism (PE). It is the first VCF to ...
Cached Medicine Technology:Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 2Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 3Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 4Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial 2
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., ... resulting in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and ... the University of Illinois, and then went on to earn his title of Doctor ...
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... The ... Kybella™. It is the first and only nonsurgical product approved by the Food ... Dr. Vito Quatela and Dr. William Koenig are among the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams ... good people, all for a good cause. In its second year, the “Music With ... by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, May ... American adults with attention-deficit hyperactivity disorder (ADHD), or the parents ... before finding one that carries the prescription they need to ... affected vary, but much of the focus has been on ...
... Men and women infected with HIV reduced the risk of ... antiretroviral medicines when their immune systems were relatively healthy, according ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... known as HPTN 052, was slated to end in 2015 ...
... . , Neural stem cells can do a lot, but ... usually generated by neural stem cells of the peripheral nervous system, ... nervous system from the stem cells of the brain. However, researchers ... the Max Planck Institute of Immunobiology and Epigenetics in Freiburg have ...
... multicentre study, headed by researchers from Karolinska Institutet in ... mesh can be more effective than traditional surgery. The ... anatomy and more efficient symptom relief, although there is ... published in the renowned scientific periodical The New ...
... a genetic basis, at least in part. A region in ... a key role in this process, as Dr. Ins Ibaez-Tallon ... Medicine (MDC) Berlin-Buch, Germany, have now shown. They also shed ... Neuron , May,12, 2011, Vol. 70, Issue 3, pp: 522-535; ...
... (HealthDay News) -- Giving adrenalin to people with snakebites ... research finds. There,s a high rate of acute ... But giving low-dose adrenaline to patients who have been ... the risk of severe allergic reactions. The ...
Cached Medicine News:Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 2Health News:ADHD Drug Shortage Has Patients, Parents Scrambling 3Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 2Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 3Health News:Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners 4Health News:A new program for neural stem cells 2Health News:A new program for neural stem cells 3Health News:Synthetic mesh can improve outcome of prolapse surgery 2Health News:Reining in nicotine use 2Health News:Treat Snakebites With Adrenaline, Study Says 2
Bougie Urethrotomes for slitting the female urethra and for meatus stenosis in males...
OES Pro Optical Urethrotome...
ACMI urethrotomes are available in two distinct styles to meet your specific professional needs. The Classic Series™ Otis Urethrotome consists of a blade, straight tip, and ball tip, with an av...
... Stryker's cystoscope line combines ... intuitive and durable hardware. ... incorporate a robust, ergonomic ... connection found on Stryker ...
Medicine Products: